Literature DB >> 48413

Grading of prostatic carcinoma.

F K Mostofi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 48413

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


× No keyword cloud information.
  16 in total

1.  Nuclear protein as a prognostic factor of growth activity in prostatic adenocarcinoma.

Authors:  G R Dohle; J A Beekhuis; G J van Steenbrugge; F H Schröder; H J Tanke
Journal:  Urol Res       Date:  1996

2.  Shift of tumor features in patients with clinically localized prostate cancer undergoing radical prostatectomy since the beginning of the PSA era.

Authors:  Herbert Augustin; Marco Auprich; Philipp Stummvoll; Katja Lipsky; Karl Pummer; Peter Petritsch
Journal:  Wien Klin Wochenschr       Date:  2006-06       Impact factor: 1.704

3.  Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens.

Authors:  M P Gallee; E Visser-de Jong; J A van der Korput; T H van der Kwast; F J ten Kate; F H Schroeder; J Trapman
Journal:  Urol Res       Date:  1990

4.  High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: results of a retrospective analysis.

Authors:  Ryoong-Jin Oh; Yasuo Yoshioka; Eiichi Tanaka; Hiroya Shiomi; Iori Sumida; Fumiaki Isohashi; Osamu Suzuki; Koji Konishi; Yoshifumi Kawaguchi; Satoaki Nakamura; Masahiro Kato; Takehiro Inoue
Journal:  Radiat Med       Date:  2006-01

5.  The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer.

Authors:  M Rudoni; G Antonini; M Favro; A Baroli; M Brambilla; G Cardani; L Ciardi; G M Sacchetti; E Inglese
Journal:  Eur J Nucl Med       Date:  1995-03

Review 6.  Reproducibility and reliability of tumor grading in urological neoplasms.

Authors:  Rainer Engers
Journal:  World J Urol       Date:  2007-09-09       Impact factor: 4.226

7.  Histologic grading of prostatic adenocarcinoma: intraobserver reproducibility of the Mostofi, Gleason and Böcking grading systems.

Authors:  M L Cintra; A Billis
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

8.  The serum levels of testosterone and prolactin in patients with prostatic carcinoma treated with various doses of Fostrolin and bromocriptin.

Authors:  L Jeromin
Journal:  Int Urol Nephrol       Date:  1982       Impact factor: 2.370

9.  Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma.

Authors:  N Konishi; Y Hiasa; H Matsuda; M Tao; T Tsuzuki; I Hayashi; Y Kitahori; T Shiraishi; R Yatani; J Shimazaki
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

10.  Cell kinetic and cytological grading of prostatic carcinoma.

Authors:  B Helpap
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.